Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
PF 6274484 is a high affinity and potent covalent EGFR kinase inhibitor (Ki = 0.14 nM). Inhibits autophosphorylation of WT and mutant EGFR in tumor cells (IC50 values are 5.8 and 6.6 nM, respectively).
Sold for research purposes under agreement from Pfizer Inc.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Schwartz et al (2014) Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance. Proc.Natl.Acad.Sci.U.S.A. 111 173 PMID: 24347635
Keywords: PF 6274484, PF 6274484 supplier, PF6274484, epidermal, growth, factor, receptors, EGFR, kinase, inhibitors, inhibits, potent, high, affinity, covalent, 5939, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for PF 6274484.
There are currently no reviews for this product. Be the first to review PF 6274484 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.